Date	Title	Document
Date 12/22/21	Title Relistor® (Methylnaltrexone Bromide) Data is Published in the Journal of Emergency Medicine	Document PDF
Date 12/06/21	Title APMA Grants Seal of Approval for JUBLIA® (efinaconazole) Topical Solution, 10%	Document PDF
Date 12/03/21	Title Salix Brings Educational Resources on Constipation Into the Homes of Patients and Caregivers for Constipation Awareness Month	Document PDF
Date 11/15/21	Title Bausch + Lomb Reports More Than 41 Million Units Of Contact Lens, Eye And Lens Care Materials Recycled Through ONE By ONE And Biotrue® Eye Care Recycling Programs	Document PDF
Date 11/11/21	Title Salix Will Share New Rifaximin Data At AASLD's The Liver Meeting™ 2021	Document PDF
Date 11/04/21	Title Bausch Health Announces Participation In Upcoming Investor Conferences	Document PDF
Date 11/02/21	Title Bausch Health Companies Inc. Announces Third-Quarter 2021 Results	Document pdf
Date 11/01/21	Title Bausch + Lomb Will Present Scientific Data and Analyses During the American Academy of Ophthalmology and American Academy of Optometry Annual Meetings	Document PDF
Date 10/27/21	Title Bausch + Lomb Launches Biotrue® Eye Care Recycling Program in Collaboration With TerraCycle in the United States	Document PDF
Date 10/25/21	Title New Report Reveals Barriers To Quality Care For Chronic Liver Disease Patients, A Cause Of Morbidity And Mortality Projected To Grow In The United States	Document PDF
Date 10/25/21	Title Salix Will Feature New Data At The American College Of Gastroenterology® 2021 Annual Scientific Meeting	Document PDF
Date 10/25/21	Title Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis	Document PDF
Date 10/21/21	Title Bausch Health Announces Tom Vadaketh Will Join Bausch Pharma* As Chief Financial Officer	Document PDF
Date 10/19/21	Title Ortho Dermatologics To Present New Data At The 2021 Fall Clinical Dermatology Conference	Document PDF
Date 10/06/21	Title Bausch Health Companies Inc. Will Release Third-Quarter 2021 Financial Results On November 2	Document PDF
Date 09/30/21	Title Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 (perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland Dysfunction	Document PDF
Date 09/29/21	Title Bausch Health Releases Annual Environmental, Social and Governance Report	Document PDF
Date 09/02/21	Title Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At PAINWeek 2021	Document PDF
Date 09/01/21	Title Bausch Health Announces Participation In Upcoming Investor Conferences	Document PDF
Date 08/03/21	Title Bausch Health Companies Inc. Announces Second-Quarter 2021 Results	Document pdf
Date 08/03/21	Title Bausch Health Announces Plans To Pursue An Initial Public Offering Of Solta Medical	Document PDF
Date 08/03/21	Title Bausch Health To Reduce Debt By $350 Million	Document PDF
Date 08/02/21	Title Bausch Health Completes Sale Of Amoun Pharmaceutical To ADQ	Document PDF
Date 07/29/21	Title Ortho Dermatologics Announces 2021 Aspire Higher Scholarship Recipients	Document PDF
Date 07/22/21	Title Salix Announces 2021 Gastrointestinal Health Scholars Program Winners	Document PDF
Date 07/19/21	Title Bausch + Lomb Will Present 14 Scientific Posters Featuring New Analyses Involving Its Surgical Technologies At The 2021 Annual Meeting Of The American Society Of Cataract And Refractive Surgery	Document PDF
Date 07/12/21	Title Bausch + Lomb Launches Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes	Document PDF
Date 07/07/21	Title Bausch + Lomb Completes Enrollment Of Second Phase 3 Study For NOV03 (perfluorohexyloctane)	Document PDF
Date 07/06/21	Title Bausch Health Companies Inc. Will Release Second-Quarter 2021 Financial Results On August 3	Document PDF
Date 07/01/21	Title Bausch Health To Reduce Debt By $150 Million Using Cash Generated From Operations	Document PDF
Date 06/23/21	Title Bausch + Lomb Expands Parameters for Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses	Document PDF
Date 06/22/21	Title Bausch Health Announces Extension Of Its Tender Offer For Cash Tender Offer For Senior Secured Notes By One Business Day To Reflect The Federal Holiday On June 18, 2021	Document PDF
Date 06/21/21	Title Bausch Health Announces D. Robert Hale Has Resigned From Its Board Of Directors	Document PDF
Date 06/08/21	Title Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of eyeTELLIGENCE™ Clinical Decision Support Software	Document PDF
Date 06/07/21	Title Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offer For Senior Secured Notes	Document PDF
Date 06/02/21	Title Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension)	Document PDF
Date 06/01/21	Title Bausch + Lomb and Prevent Blindness Launch Educational Campaign During Cataract Awareness Month	Document PDF
Date 05/27/21	Title Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations	Document PDF
Date 05/25/21	Title Bausch Health Announces Participation At The Jefferies Healthcare Conference	Document PDF
Date 05/24/21	Title Bausch Health Announces Pricing Of Private Offering Of Senior Secured Notes	Document PDF
Date 05/24/21	Title Bausch Health Commences Cash Tender Offer For Any And All Of Its 7.00% Senior Secured Notes Due 2024	Document PDF
Date 05/24/21	Title Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes And Conditional Redemption Of Existing Senior Secured Notes	Document PDF
Date 05/17/21	Title Salix Will Feature New Data At Digestive Disease Week® 2021	Document PDF
Date 05/11/21	Title New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues To Reduce The Risk Of Moderate To Advanced Age-Related Macular Degeneration Progression	Document PDF
Date 05/06/21	Title Bausch Health Announces Participation In Upcoming Investor Conferences	Document PDF
Date 05/04/21	Title Bausch Health Companies Inc. Announces First-Quarter 2021 Results	Document pdf
Date 05/03/21	Title Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations	Document PDF
Date 04/29/21	Title Bausch + Lomb Will Present New Scientific Data And Analyses On Products And Pipeline Programs During The Association For Research In Vision And Ophthalmology Meeting	Document PDF
Date 04/28/21	Title Bausch Health Announces 2021 Annual Meeting of Shareholder Results	Document PDF
Date 04/27/21	Title Bausch Health Issues Form 8-K for 2021 Annual Meeting of Shareholders Presentation	Document PDF
Date 04/22/21	Title Ortho Dermatologics Announces Statistically Significant Topline Results From Second Pivotal Phase 3 Clinical Trial Evaluating IDP-126 Gel In Acne Vulgaris	Document PDF
Date 04/21/21	Title Ortho Dermatologics to Present New Data at the AAD VMX 2021, Virtual Meeting Experience	Document PDF
Date 04/16/21	Title Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved In Brazil	Document PDF
Date 04/15/21	Title New Report Reveals That More Than One-Third Of IBS Patients Surveyed State It Has Been More Challenging To Manage Their Symptoms During The COVID-19 Pandemic	Document PDF
Date 04/13/21	Title Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction	Document PDF
Date 04/09/21	Title Bausch Health Companies Inc. Will Release First-Quarter 2021 Financial Results On May 4	Document PDF
Date 04/08/21	Title Bausch Health Launches ENVIVE™ Daily Probiotic Supplement	Document PDF
Date 04/07/21	Title FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device	Document PDF
Date 04/07/21	Title Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations	Document PDF
Date 03/31/21	Title Bausch Health Agrees To Sell Amoun Pharmaceuticals	Document PDF
Date 03/30/21	Title Salix Launches GastroHub for Advanced Practice Providers, an Educational Website Designed To Provide Nurse Practitioners and Physician Assistants With Relevant Information for Treating IBS-D and HE	Document PDF
Date 03/11/21	Title Bausch Health Announces CFO Succession Plan	Document PDF
Date 03/09/21	Title Bausch Health Publishes Pipeline Update For The Barclays Global Healthcare Conference	Document PDF
Date 03/08/21	Title Solta Medical Announces the U.S. Launch of The Clear + Brilliant® Touch Laser	Document PDF
Date 03/01/21	Title Colon Cancer Coalition and Salix to Launch a Year-Long Campaign to Raise Awareness About the Importance of Colorectal Cancer Screenings	Document pdf
Date 02/26/21	Title Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations	Document PDF
Date 02/24/21	Title Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2020 Results And Provides 2021 Guidance	Document pdf
Date 02/24/21	Title Bausch Health Announces Agreement With Carl C. Icahn	Document PDF
Date 02/23/21	Title Bausch + Lomb Launches Alaway® Preservative Free Antihistamine Eye Drops	Document PDF
Date 02/22/21	Title Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations	Document PDF
Date 02/18/21	Title Salix Announces 2021 Gastrointestinal Health Scholars Program	Document PDF
Date 02/16/21	Title Bausch Health Announces Participation In Upcoming Investor Conferences	Document PDF
Date 02/11/21	Title Bausch Health Responds To Schedule 13D Filing From Icahn Capital LP	Document PDF
Date 02/09/21	Title Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in South Korea	Document PDF
Date 02/02/21	Title Ortho Dermatologics Announces 2021 Aspire Higher Scholarship Program	Document PDF
Date 02/01/21	Title Prevent Blindness and Bausch + Lomb to Launch Year-Long Video Series to Raise Awareness of Age-Related Macular Degeneration (AMD)	Document PDF
Date 01/27/21	Title Bausch Health Companies Inc. Will Release Fourth-Quarter And Full-Year 2020 Financial Results On February 24	Document PDF
Date 01/21/21	Title South Korea's MFDS Approves LUMIFY® Eye Drops	Document PDF
Date 01/20/21	Title Bausch + Lomb Announces Scientific Data On Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses To Be Presented At The Virtual Global Specialty Lens Symposium	Document PDF
Date 01/19/21	Title Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (perfluorohexyloctane)	Document PDF
Date 01/12/21	Title Bausch Health Provides Preliminary Update On Fourth-Quarter And Full-Year 2020 Financial Results And Business Recovery	Document PDF
Date 01/06/21	Title Bausch Health To Participate At The 39th Annual J.P. Morgan Healthcare Conference	Document PDF